Tocagen June 2015 Newsletter
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
This edition of the Tocagen newsletter shows that the company has a lot of confidence in their brain tumor treatment. They added Dr. Das as vice president of clinical development and medical affairs. She played a huge part in the FDA approval process for Avastin for GBMS.
They also got approval from the FDA to start a newtrial which if successful will allow them to apply for FDA approval. The newsletter also has links to a lot of presentations made about this treatment, and also mentions the Musella Foundation! (We gave a grant to support preclinical testing of Toca 511 with 5-ALA or tumor treating fields!)
(Disclaimer: Tocagen is a sponsor of our organization)
Posted on: 07/01/2015
Click HERE to return to brain tumor news headlines